Sterling Pharma Solutions
Address: Dudley, Cramlington, NE23 7QGSocial Media
Facebook : https://www.facebook.com/pages/Shasun-Pharmaceuticals-Ltd/444501305593892?fref=tsAbout Us
Sterling Pharma Solutions Ltd is a full service API CDMO offering services from the discovery through to commercial manufacture.
US FDA, MHRA and PMDA approved facilities; SPS can handle the most hazardous chemistries at a range of scales. We are passionate about providing a customer focussed and service driven approach to offer flexible and tailored solutions to our clients.
Sectors
- Contract Research & Development
- Contract Manufacturing
Categories
- Drug Development Services
- Active Pharmaceutical Ingredients
- Chemical Synthesis-cGMP
- Process Development
- Bioprocess Development
- Small Molecule Synthesis
- Small Molecules
- Biologics
- Custom Synthesis
- Chiral Products
- Fluorination
- Antibody Drug Conjugates
- Bioconjugation
- Drug Conjugates & Linkers
- Solid State Research
- Crystal Structure Analysis
- Crystallisation
- Milling
- Micronisation
Certifications
- GMP-Awarded by National Authority
- GMP-USA-FDA-Inspected
- GMP-Japan-PMDA-Inspected
- GMP-United Kingdom-MHRA-Inspected
- GMP-United Kingdom-Investigational Medicinal Products Licence-Inspected
News
Kivu Bioscience, Sterling Pharma Solutions Enter Manufacturing Pact
Kivu Bioscience, a biotech company developing next-gen antibody-drug conjugates (ADCs), entered a manufacturing agreement with Sterling Pharma Solutions, a global CDMO, to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology ADC candidate, KIVU-107.
Sterling will manufacture cGMP clinical material for KIVU-107 at its dedicated bioconjugation facility in Deeside, UK. The collaboration includes process familiarization, analytical development, process optimization, and scale-up activities in preparation for a cGMP manufacturing campaign.
Synergie Environ work with Sterling Pharma Solutions in a UK First Sustainability Solution
North East based Sterling Environmental Solutions, part of Sterling Pharma Solutions, has commissioned an £8m anaerobic digestion (AD) plant, which is the first of it’s kind in the UK, supporting the company’s aim for carbon neutrality.
Sterling Pharma Solutions Acquires UK Contract Research Organisation, NewChem Technologies
Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has completed the acquisition of UK-based NewChem Technologies, a contract services provider focused on organic chemistry and supplying customers across a range of industries from pharmaceuticals, diagnostics and biotechnology to veterinary science and chemicals.
GHO Capital and Partners Group invest in Sterling Pharma Solutions
London, UK – 25 May 2023: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, and Partners Group, a leading global private markets firm, acting on behalf of its clients, today announce an investment in GHO portfolio company Sterling Pharma Solutions (“Sterling” or “the Company”), a global Contract Development and Manufacturing Organisation (“CDMO”).
Sterling Pharma Solutions, has commenced production of hydroxychloroquine
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has commenced production of hydroxychloroquine (HCQ), a treatment currently under investigation for COVID-19.
Sterling will be manufacturing the active pharmaceutical ingredient (API) with the finished product being manufactured and supplied by Accord Healthcare.
The UK’s current supply of HCQ is sourced from overseas, primarily as a result of economic pressures driving production to lower cost manufacturing regions. This new deal with Accord will establish a domestic supply of the product ensuring access for patients in the UK, should the drug prove successful.
Kevin Cook CEO at Sterling Pharma Solutions said, “While it is currently unclear whether HCQ will be a viable treatment for COVID-19, it is vital to proactively establish a strong supply route ahead of time.
“Rapid response to a rapidly changing landscape has been key here. We have worked quickly alongside Accord Healthcare to establish a UK supply chain for this product.
“HCQ could potentially provide an effective treatment for COVID patients and during such an unprecedented time it’s important that the pharmaceutical industry works flexibly to achieve maximum results as quickly as possible and this partnership is a good example of that.”
Sterling has already supported Accord with the purchase of over 50 tonnes of the key raw materials, which equates to roughly 60 million finished tablets of HCQ.
As a result of the partnership Accord expects to supply up to 50 million HCQ tablets per month and has already started production of HCQ from its manufacturing facility in Barnstable, UK.
Sterling Pharma Solutions is investing £6m into its pilot plant facility at its UK site
Shasun Appoints Kevin Cook to Accelerate Business Growth
2013 with a remit to accelerate company growth and increase sales.
Shasun Pharmaceuticals Ltd And Debiopharm Group™ Enter Into Licensing Agreement----
Job Vacancies
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com